Universität zu Köln

Journal Article

Eiger, D., Maurer, C., Brandao, M., Aftimos, P. G., Punie, K., Taylor, D., Van den Mooter, T., Poncin, R., Canon, J-L., Duhoux, F., Casert, V., Clatot, F., Velghe, C., Craciun, L., Paesmans, M., de Azambuja, E., Ignatiadis, M., Larsimont, D., Piccart, M. and Buisseret, L. (2020). First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann. Oncol., 31. S. S386 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041